Belimumab Phase I Study in Chinese Subjects With Systemic Lupus Erythematosus
NCT02880852
·
clinicaltrials.gov ↗
PHASE1
Phase
COMPLETED
Status
20
Enrollment
INDUSTRY
Sponsor class
Conditions
Systemic Lupus Erythematosus
Interventions
DRUG:
Belimumab
Sponsor
GlaxoSmithKline